Home › Amgen First To Win EU Backing For New Kind Of Cholesterol Drug
 

Keywords :   


Amgen First To Win EU Backing For New Kind Of Cholesterol Drug

2015-05-22 15:59:36| Biotech - Topix.net

Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA. Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that have the potential to drastically reduce the risk of heart attacks when used in addition to standard treatment.

Tags: of kind win drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05BeautyHealth: Q1 2024 Financials
10.05Research Institute for Fragrance Materials to Promote Online Database on May 22
10.05Hairstory Promotes Dina Rosenbloom To Chief Executive Officer
10.05Net Sales Decrease 5% for The Clorox Company in Q3 2024
10.05Sunak says it'll take time for people to feel better
10.05Alabama second state to ban lab-grown meat
10.05Alabama second state to ban lab-grown meat
10.05Senators request more aggressive approach on HPAI countermeasures
More »